INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

14th International Conference on Malignant Lymphoma

 

14-17 June 2017, Lugano
Close
N. Poster
Poster title
Applicant name
Status
  140-P Whole-exome-sequencing of nodal marginal zone lymphomas identifies recurrent molecular lesions in genes involved in chromatin remodelling and NOTCH signalling Vincent Pillonel Received Received
  141-P Integrative mutational analysis of Pediatric-Type Follicular Lymphoma reveals TNFRSF14 and MAP2K1 as the most frequently mutated genes Janine Schmidt Received Received
  143-P NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE (MRD) MONITORING IN MANTLE CELL AND FOLLICULAR LYMPHOMA: THE TARGETED LOCUS AMPLIFICATION (TLA) NGS STRATEGY Simone Ferrero Received Received
  144-P Host Genetic Variation in the TNF and NF-?B Pathways and Prognosis in Mantle Cell Lymphoma: An Analysis of Two Studies Yucai Wang Received Received
  148-P Kras and Ago2 interaction promotes initiation of plasmablastic lymphoma Kevin Thai Received Received
  149-P Comprehensive epigenetic and transcriptional survey of the imprintome in normal B-cells and germinal center derived B-cell lymphomas in the framework of the MMML and ICGC MMML-Seq networks Susanne Bens Received Received
  150-P Gene expression profiling and mutation analysis can aid treatment decision making in aggressive B cell lymphoma patients Cathy Burton Received Received
  151-P Application of cell-of-origin subtypes determined by digital gene expression in HIV-related diffuse large B-cell lymphomas Maria Joao Baptista Received Received
  152-P BIODLCL04: THE PROGNOSTIC ROLE OF CELL OF ORIGIN PROFILE, MYC, BCL2 AND TP53 IN UNTREATED POOR-RISK DIFFUSE LARGE B-CELL LYMPHOMA. ANNALISA CHIAPPELLA Received Received
  153-P Prognostic significance and correlation to gene expression profile of EZH2 mutations in diffuse large B-cell lymphoma (DLBL) in two large prospective studies Thomas Cummin Received Received
  154-P Preliminary evidence of a molecular predictor of tazemetostat response, beyond EZH2 mutation, in NHL patients via characterization of archive tumor and circulating tumor DNA Stephen Blakemore Received Received
  155-P Array-based DNA methylome analyses of primary lymphomas of the central nervous system Julia Vogt Received Received
  159-P Identification and characterisation of the lymphoma initiating cell (LIC) population in an ALCL mouse model Anna Lena Illert Received Received
  160-P Oncogenic Activation of STAT3 Pathway Drives PD-L1 Expression in Natural Killer/T cell Lymphoma Tammy Song Received Received
  161-P SAMHD1 is frequently involved in T-cell Prolymphocytic Leukemia (T-PLL) pathogenesis Patricia Johansson Received Received
  164-P Focal skeletal 18F-FDG uptake characterizes a subset of classical Hodgkin lymphoma patients with poor outcome - A Danish-Swedish study of 209 newly diagnosed patients Mette Abildgaard Pedersen Received Received
  165-P Histological verification of positive positron emission tomography findings during the follow-up of patients with mediastinal lymphoma: large experience on 96 patients Pier Luigi Zinzani Received Received
  166-P SAFETY AND EFFICACY ANALYSIS OF ELDERLY PATIENTS TREATED WITHIN THE GATLA HL-05 CLINICAL TRIAL: PET adapted therapy after 3 cycles of ABVD for all stages of Hodgkin Lymphoma Astrid Pavlovsky Received Received
  167-P Allogeneic transplantation in Hodgkins lymphoma after a failed autograft: long term outcomes and graft-versus-host disease free/relapse-free survival (GRFS) Francesco Spina Received Received
  169-P Real life experience with brentuximab vedotin: the Italian study on 234 relapsed/refractory Hodgkins lymphoma Pier Luigi Zinzani Received Received
  170-P A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy followed by 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma Anita Kumar Received Received
  172-P Mortality rates remain increased in young patients with classical Hodgkin lymphoma even after years in remission: Results from a Nordic Lymphoma Group Study Jorne Biccler Received Received
  173-P Predicted Cardiac and Second Cancer Risks in Hodgkin Lymphoma Patients Treated with Advanced Proton Beam Therapy Compared to Photon Radiotherapy. Georgios Ntentas Received Received
  174-P Cardiac disease prediction following Hodgkin lymphoma: An EORTC Lymphoma Group and GELA follow-up study Maja Maraldo Received Received
  175-P Usefulness of N-terminal brain natriuretic peptide levels and FRESCO scale for the prediction of anthracycline-induced cardiomyotoxicity in patients with Hodgkin Lymphoma Mariana Ferraro Received Received
  178-P Autoimmune Disease (AID) is both a Risk Factor and a Prognostic Factor Affecting Survival in Patients with B-Cell Non-Hodgkin Lymphoma (NHL) Ora Paltiel Received Received
  179-P Microenvironmental features reflecting immunocompetence are strong outcome determinants in HIV-associated lymphoma Maja Vase Received Received
  180-P Outcome Prediction in Diffuse Large B-cell Lymphoma Can Be Greatly Improved by Alternative Use of Clinical Information: A Nordic Lymphoma Group Study Jorne Biccler Received Received
  181-P Simultaneous Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) at the Diagnosis has similar outcome as DLBCL Katerina Benesova Received Received
  182-P High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials Patrick Reagan Received Received
  183-P LONG-TERM FOLLOW-UP AFTER LOCALIZED RADIOTHERAPY IN PATIENTS WITH TRANSFORMED B-CELL LYMPHOMA TREATED WITH RITUXIMAB-CONTAINING CHEMOTHERAPY Kenji Nozaki Received Received
  184-P Obinutuzumab-miniCHOP for the Treatment of Elderly Unfit Patients with Diffuse Large B-Cell Lymphoma. A study of the Fondazione Italiana Linfomi. Caterina Mammi Received Received
  185-P End of treatment PET-CT predicts progression free survival in DLBCL after first-line treatment: results from the Phase III GOYA study Madeleine Wilde Received Received
  186-P Rituximab SC and IV plus CHOP show similar efficacy and safety in the randomised MabEase study in first-line DLBCL Madeleine Wilde Received Received
  187-P R-COMP vs. R-CHOP AS FIRST-LINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA IN PATIENTS OLDER THAN 60 YEARS: RESULTS FROM A RANDOMIZED PHASE 2 STUDY FROM THE SPANISH GELTAMO GROUP Juan-Manuel Sancho Received Received
  188-P Anthracycline Dose Intensification in Diffuse Large B-cell Lymphoma Pengpeng Xu Received Received
  189-P Phase 2 randomized trial comparing standard RCHOP versus BRCAP as first line treatment in young patients with high-risk DLBCL. A study from Spanish Group GELTAMO ANA MARQUEZ Received Received
  191-P Rituximab, lenalidomide, and ibrutinib alone and combined with chemotherapy for patients with newly diagnosed diffuse large B-cell lymphoma Jason Westin Received Received
  194-P Bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: Final analysis of a phase 2 study from GELTAMO Alejandro Martín Received Received
  195-P Reduced intensity (FB2) vs reduced toxicity myeloablative (FB3-4) fludarabine/busulfan based conditioning regimens for non-Hodgkin lymphoma (NHL) allografted patients. Amandine Le Bourgeois Received Received
  196-P Double-expressor lymphomas do not have inferior outcome after autologous stem cell transplant in the first line treatment. Marie Trnkova Received Received
  197-P Direct-acting Antivirals during or after Immuno-chemotherapy in Hepatitis C Virus-associated Diffuse Large B-cell Lymphomas Michele Merli Received Received
  198-P Current therapy of secondary CNS involvement in malignant lymphoma: Data from a multicenter prospective international registry Agnieszka Korfel Received Received
  199-P Validation of the CNS International Prognostic Index in a Large Asian Cohort Data from the Singapore Lymphoma Study Group yuh shan Lee Received Received
  202-P Dose-dense chemoimmunotherapy and CNS prophylaxis in patients with high-risk DLBCL: a comparison of Nordic CRY-04 and CHIC studies Sirpa Leppa Received Received
  203-P Anti-infective prophylaxis with aciclovir and cotrimoxazole significantly reduces the rate of infections and therapy-associated deaths in elderly patients with DLBCL undergoing R-CHOP immunochemotherapy Niels Murawski Received Received
  204-P Frequency of perforation & impact of bowel rest in aggressive non-Hodgkin lymphoma with gastrointestinal involvement: an international, multi-center retrospective study. Collin Chin Received Received
  205-P Long Term Follow-Up and Update for Patients Enrolled in ECOG 1405 Nadia Khan Received Received
  206-P Mantle cell lymphoma of mucosa associated lymphoid tissue: a retrospective multicenter observational study of the European Mantle Cell Lymphoma Network Lucia Morello Received Received
  208-P R-CHOP / R-HDAC and rituximab maintenance results in high complete remission rate, minimal residual disease negativity, and excellent survival in elderly MCL patients Pavel Klener Received Received
  209-P Maintenance rituximab improves survival in newly diagnosed mantle cell lymphoma patients: analysis of the Czech Lymphoma Study Group Ale Obr Received Received
  210-P Rituximab Maintenance after Nordic Protocol (R-MaxiCHOP/HD-AraC/ASCT) Significantly Prolongs Survival in Young Mantle Cell Lymphoma Patients Pavel Klener Received Received
  211-P SAKK 36/13 - Ibrutinib and bortezomib followed by ibrutinib maintenance in patients with relapsed and refractory mantle cell lymphoma: Phase I report of a Phase I/II trial Urban Novak Received Received
  212-P Phase I/II clinical trial of a tumor cell vaccine followed by vaccine-primed lymphocyte infusion for patients with Mantle Cell Lymphoma Matthew Frank Received Received
  213-P Obinutuzumab plus Ibrutinib in relapse/refractory mantle cell lymphoma patients: first results of the Oasis phase I trial. STEVEN LE GOUILL Received Received
  214-P Rituximab maintenance after autologous stem cell transplantation in patients with mantle cell lymphoma, final result of the LyMa trial conducted on behalf the LYSA group Steven Le Gouill Received Received
  217-P Progression-free survival following lenalidomide-based treatment is significantly longer in extragastric than in gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) Barbara Kiesewetter Received Received
  219-P Treatment with combination of lenalidomide and rituximab achieves durable responses in a long term follow up of patients with indolent non-hodgkins lymphoma Maria Chaudhry Received Received
  220-P Minimal residual disease and outcomes in relapsed/refractory follicular lymphoma (FL) in the Phase III GADOLIN trial of obinutuzumab and bendamustine vs bendamustine Madeleine Wilde Received Received
  221-P R-CP chemoimmunotherapy in patients with IgM paraproteinaemic neuropathy produces improvements in functional, electrophysiological and serological outcomes. Andrew Duncombe Received Received
  222-P Bendamustine-rituximab (BR) versus R-CHOP as upfront therapy for indolent B-cell lymphomas: a comparative, population-based analysis Adam Olszewski Received Received
  223-P A DOUBLE-BLIND, RANDOMIZED PHASE 3 STUDY TO COMPARE EFFICACY AND SAFETY OF CT-P10 TO RITUXIMAB IN COMBINATION WITH CVP IN PATIENTS WITH ADVANCED-STAGE FOLLICULAR LYMPHOMA EunJin Choi Received Received
  224-P Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation at rituximab era PIERRE SESQUES Received Received
  225-P Autologous Stem Cell Transplantation may potentially abrogate the negative prognostic effect of early relapse after chemo or inmunochemotherapy in Follicular Lymphoma Ana Jiménez Ubieto Received Received
  226-P Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis CARLA CASULO Received Received
  227-P Minimal residual disease (MRD) in early stage follicular lymphoma can predict prognosis and drive rituximab treatment after radiotherapy ALESSANDRO PULSONI Received Received
  228-P Low Grade B-cell Non-Hodgkin Lymphomas involving the Central Nervous System: An Analysis from the National Cancer Database Priyanka Pophali Received Received
  230-P Patients with follicular lymphoma (FL) in maintained complete response (CR) at 30 months show a survival similar to a sex- and age-matched Spanish general population Laura Magnano Mayer Received Received
  231-P POD24 and CR30 are promising surrogate endpoints for assessing the outcome of patients with advanced stage Follicular Lymphoma enrolled in the FOLL05 trial by FIL. Martina Manni Received Received
  232-P Defining progression free survival after multiple lines of therapy and impact of dynamic changes in FLIPI for multiply relapsed Follicular lymphoma in the Rituximab era Connie Batlevi Received Received
  233-P Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma Jacob Soumerai Received Received
  234-P Statin use and prognosis in 12,865 non-Hodgkin lymphoma patients treated in the Rituximab-era Elsa Brnvall Received Received
  235-P Ibrutinib Increases the Systemic Exposure of Rituximab: Pharmacokinetic Results from the HELIOS Trial Laurie Orloski Received Received
  239-P Outcomes with Bruton Tyrosine Kinase Inhibition in relapsed / refractory chronic lymphocytic leukemia / small lymphocytic lymphoma after progression on venetoclax Mary Ann Anderson Received Received
  240-P Outcomes of patients post ibrutinib treatment for relapsed / Refractory CLL: A UK and Ireland analysis George Follows Received Received
  241-P Ibrutinib For Relapsed / Refractory CLL: An update of the UK And Ireland Analysis Of Outcomes In 315 Patients George Follows Received Received
  244-P Outcome of patients with relapsed and refractory peripheral T cell lymphoma intended for stem cell transplant Stephen Parkin Received Received
  245-P A multi-center study of GLIDE chemotherapy consolidated with autologous stem cell transplantation for newly diagnosed stage IV and relapsed extranodal natural killer/T-cell lymphoma patients Jie Ji Received Received
  246-P Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Patients with Relapsed/Refractory Systemic Anaplastic Large Cell Lymphoma (R/R sALCL). A Retrospective Analysis of the Lymphoma Working Party-EBMT. Eva Domingo Domenech Received Received
  247-P Risk stratification based on NCCN-IPI at the time of diagnosis in combination with post-treatment PET-CT scan for the treatment of nodal peripheral T-cell lymphoma Ho-Young Yhim Received Received
  252-P Prognostic factors in patients with relapsed or refractory systemic anaplastic large T-cell lymphoma (ALCL) receiving brentuximab vedotin and outcome after treatment failure. Yasuhiro Oki Received Received
  253-P Case Match Control Analysis of PROPEL Reveals a Survival Advantage for Patients with Relapsed PTCL Receiving Pralatrexate: A Novel Approach to Benchmark Drugs in Rare Diseases Owen OConnor Received Received
  254-P A Post-marketing Surveillance Study of 703 Patients Treated with Chidamide for Peripheral T-cell Lymphoma (PTCL) in China HDAC Study Group of Union for China Lymphoma Investigators(UCLI) Jian Chen Received Received
  255-P Preliminary results from an open-label, phase II study of tipifarnib in relapsed or refractory peripheral T-cell lymphoma. Catherine Scholz Received Received
  256-P Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: Interim results of postmarketing all-case surveillance Satoshi Yurimoto Received Received
  257-P Targeting the T-cell receptor -constant domain for immunotherapy of T-cell malignancies Paul Maciocia Received Received
  258-P Development of novel, non-toxic rifamycins that reverse drug resistance in diffuse large B-cell lymphoma (DLBCL) Steve Maxwell Received Received
  260-P Dual inhibition of EZH2 and HDAC is synergistic in EZH2 dysregulated lymphomas Jennifer Lue Received Received
  261-P STRO-001, A NOVEL ANTI-CD74 ANTIBODY DRUG CONJUGATE (ADC) FOR TREATMENT OF B-CELL NON-HODGKINS LYMPHOMAS (NHL) Arturo Molina Received Received
  263-P Copanlisib in combination with anti-PD-1 induces regression in animal tumor models insensitive or resistant to the monotherapies of PI3K and checkpoint inhibitors Ningshu Liu Received Received
  264-P PD--1 immune checkpoint blockade improves anti--CD20 based immunotherapy in follicular lymphoma cédric rossi Received Received
  265-P Characterization and integration of mantle cell lymphoma microenvironments are determinant for the development of rational targeted therapies David Chiron Received Received
  266-P Effective therapy by anti-CD81 against B cell lymphomas engages both direct and indirect immune mechanisms Shoshana Levy Received Received
  268-P Expression of LAG-3 defines exhaustion of intratumoral PD-1 T cells and correlates with poor outcome in follicular lymphoma Zhizhang Yang Received Received
  271-P A phase I study of chimeric antigen receptormodified T cells directed against CD19 in patients with relapsed or refractoryCD19() B cell Lymphomas: interim analysis Zhitao Ying Received Received
  273-P Safety and Clinical Activity of RP6530, a Dual PI3Kd/? Inhibitor, in Patients with advanced Hematologic Malignancies: Analysis of a Phase 1 Multi-center Study Prajak Barde Received Received
  278-P Lenalidomide and Obinutuzumab with CHOP for Newly Diagnosed Diffuse Large B-cell Lymphoma: Phase I/II Results Jason Westin Received Received
  280-P The Immunologic Doublet of Lenalidomide Plus Obinutuzumab is Highly Active in Relapsed/Refractory Follicular Lymphoma, Results of a Phase I/II Study Nathan Fowler Received Received
  284-P Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory FL or DLBCL: updated results of a phase 1b/2 study Anne Nunn Received Received
  285-P YourTreatmentChoices: Fast Access to Trials Programme George Xinarianos Received Received
  286-P Increasing cross-referral and recruitment to clinical trials: a new APProach Judith Trotman Received Received
  287-P Oral Azacytidine (AZA) and Romidepsin (R) Reveals Promising Activity in Patients with Relapsed or Refractory (R/R) Peripheral T-cell Lymphoma (PTCL) Owen OConnor Received Received
  288-P CD70 expression in Cutaneous T cell lymphoma (CTCL) patients and mechanisms of action of ARGX-110 in skin: histopathological and clinical data Anna Hultberg Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
04:17
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA

14th International Conference on Malignant Lymphoma

 

14-17 June 2017, Lugano
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 14/06/2017 TO 14/06/2019
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.14ICML.2017 




PosterSessionOnline
Logo Draft
 
Logo Cert